Dieckol Ameliorates Aβ Production via PI3K/Akt/GSK-3β Regulated APP Processing in SweAPP N2a Cell

Area of Science:

• Neuroscience
• Biochemistry
• Pharmacology

Background:

• Alzheimer's disease (AD) is characterized by amyloid-beta (Aβ) peptide deposition, stemming from amyloid precursor protein (APP) processing by secretases.
• Identifying therapeutic compounds that modulate APP processing is crucial for AD treatment.

Purpose of the Study:

• To investigate the mechanism by which three phlorotannins regulate APP processing in Alzheimer's disease models.
• To determine the specific effects of dieckol on Aβ production and related signaling pathways.

Main Methods:

• Utilized Swedish mutant APP overexpressed N2a (SweAPP N2a) cells to study APP processing.
• Assessed the impact of dieckol on intra- and extracellular Aβ levels and APP-processing enzymes (BACE1, ADAM10, PS1).
• Investigated the role of the PI3K/Akt/GSK-3β signaling pathway using specific inhibitors and phosphorylation analysis.

Main Results:

• Dieckol significantly inhibited both intra- and extracellular Aβ accumulation in SweAPP N2a cells.
• Dieckol modulated the activity of key secretases (BACE1, ADAM10, PS1) and their products (sAPPα, sAPPβ), affecting both amyloidogenic and non-amyloidogenic pathways.
• Dieckol activated the PI3K/Akt pathway, leading to GSK-3β inactivation and subsequent reduction in Aβ levels, as confirmed by inhibitor studies.

Conclusions:

• Dieckol demonstrates significant potential as a therapeutic agent for Alzheimer's disease by reducing Aβ production.
• The mechanism involves the modulation of APP processing enzymes and activation of the PI3K/Akt/GSK-3β signaling pathway.
• Further research into dieckol's neuroprotective effects is warranted for AD drug development.